Most start-up drug development companies search for innovative therapies for diseases. Not Verrica, which began trading on June 15 priced at $16. Instead, ...read more
Led by Avalara, which traded up 87% its first day, the week saw six companies raise a total of $1.3 billion. Also this week, Adaptive Insights was acquired two days before its expected IPO. As of market close today, US IPOs from the last 90 days have an average...read more
Verrica Pharmaceuticals, which is developing a drug-device that eliminates viral skin lesions and warts, raised $75 million by offering 5 million shares at $15, the midpoint of the $14 to $16 range. At the IPO price Verrica commands a fully-diluted market value...read more
The second week of June is busy, as promised. Led by SaaS companies Adaptive Insights and Avalara, seven companies are scheduled to raise a combined $1.4 billion in the week ahead. ...read more
Beetle Juice: Verrica's Ancient Remedy for the 21st Century
Most start-up drug development companies search for innovative therapies for diseases. Not Verrica, which began trading on June 15 priced at $16. Instead, ...read more
US IPO Weekly Recap: 6 IPOs, an acquisition and a postponement
Led by Avalara, which traded up 87% its first day, the week saw six companies raise a total of $1.3 billion. Also this week, Adaptive Insights was acquired two days before its expected IPO. As of market close today, US IPOs from the last 90 days have an average...read more
Verrica Pharmaceuticals prices $75 million IPO at $15 midpoint
Verrica Pharmaceuticals, which is developing a drug-device that eliminates viral skin lesions and warts, raised $75 million by offering 5 million shares at $15, the midpoint of the $14 to $16 range. At the IPO price Verrica commands a fully-diluted market value...read more
US IPO Week Ahead: Adaptive Insights and Avalara lead a 7-IPO week
The second week of June is busy, as promised. Led by SaaS companies Adaptive Insights and Avalara, seven companies are scheduled to raise a combined $1.4 billion in the week ahead. ...read more